Butisol (butabarbital sodium) is a medication applied across domains where short-term symptomatic assistance is needed to manage symptoms related to heightened physiological activity and anxiety. The medication is used across therapeutic areas involving acute or disruptive symptom patterns, and may be part of symptomatic management when functional stability is temporarily affected.

The medication is relevant for managing symptoms that interfere with daily comfort, encompassing acute short-term insomnia, pronounced situational anxiety, and providing pre-procedural sedation.

“The medication is considered relevant for easing symptoms that interfere with daily functioning, supporting patients during episodes of heightened discomfort.”

Addressing Acute Sleep Onset Difficulties

Butisol is relevant for managing symptoms that interfere with daily comfort and is used when groups of symptoms, such as difficulty falling asleep and staying asleep, appear suddenly or fluctuate. It is applied in situations involving certain distressing symptoms of short-term insomnia, where the primary benefit is to assist in achieving necessary rest. This supportive relief helps patients cope more steadily with difficult episodes and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Sleep and Tension

Symptom Domain	General Benefit Provided
Acute Insomnia (short-term)	Assists with achieving necessary rest and maintaining comfort during symptomatic phases.
Situational Tension	Supports the patient by easing psychological distress and nervousness.
Pre-Procedure Anxiety	Contributes to patient comfort and easing patient distress before intervention.

Regulatory References

1. NIH MedlinePlus overview

Butisol (butabarbital sodium) eligibility is strictly defined by regulatory documents, distinguishing between populations permitted, restricted, and prohibited from use.

Contraindicated Populations

The medicine is strictly contraindicated for individuals with a known sensitivity to barbiturates or a history of manifest or latent porphyria. Furthermore, it must not be administered to patients showing premonitory signs of hepatic coma.

Restricted and Conditional Use

Several conditions necessitate caution or restriction. Patients with hepatic damage or kidney disease require careful administration and possibly reduced initial doses. Special caution is mandatory for elderly or debilitated patients due to the increased risk of confusion, excitement, and other adverse reactions. The label also specifies that use should be approached with extreme caution, if at all, for patients with a history of drug abuse, mental depression, or suicidal tendencies.

Age and Physiological Limits

Pediatric use is not explicitly established in official documents. For older adults (aged 65 and over), Butisol is often identified as a potentially inappropriate medication. The drug's use is restricted during pregnancy due to the risk of fetal damage and requires caution during lactation as it is excreted into human milk.

Interactions with Other Medicines and Products

The interaction profile of Butisol (butabarbital sodium) is strictly defined by regulatory documents based on two principal mechanisms that govern co-administration constraints: pharmacodynamic reinforcement and pharmacokinetic enzyme induction.

Additive Central Nervous System (CNS) Depression

Co-administration with other CNS depressants leads to a critical pharmacodynamic interaction that results in additive CNS depression. This effect significantly raises the official regulatory risk of profound sedation and severe respiratory depression. Substances subject to this restriction include alcohol (ethanol), opioids, benzodiazepines, and various other sedative-hypnotics or antihistamines. This combination is highly constrained due to the increased severity of the combined physiological effect.

Hepatic Enzyme Induction

Butisol functions as an inducer of hepatic microsomal enzymes (CYP system). This pharmacokinetic action increases the metabolism and subsequently reduces the plasma exposure of numerous co-administered medicines, potentially leading to a loss of therapeutic effect. Affected drug categories documented in official labeling include oral anticoagulants (e.g., Dicumarol), corticosteroids, estrogen-containing oral contraceptives, and Phenytoin.

Exposure-Modifying Agents

Certain agents, such as Monoamine Oxidase Inhibitors (MAOIs) and Chloramphenicol, may inhibit the clearance of Butisol itself, resulting in increased systemic exposure and enhanced effects of Butabarbital sodium. The official documentation also notes that the presence of food may delay the absorption of the medicine, resulting in a delayed onset of action.

Butisol (butabarbital) is a lipophilic, non-selective central nervous system depressant that readily crosses the blood-brain barrier. Its primary biological target is the GABAA receptor complex, a ligand-gated ion channel, where Butisol functions as a positive allosteric modulator at a site distinct from both the primary gamma-aminobutyric acid (GABA) and benzodiazepine binding sites. The interaction potentiates the inhibitory neurotransmitter GABA's effects.

Molecularly, Butisol's binding stabilizes an open conformation of the chloride ionophore, increasing the duration of chloride channel opening following GABA binding. This prolonged opening drives an increased flux of negatively charged chloride ions into the postsynaptic neuron, a process resulting in postsynaptic membrane hyperpolarization. This change elevates the threshold required for neuronal excitation, leading to a marked suppression of neuronal excitability and firing rate.

Downstream, this potentiation of GABAergic inhibitory tone in the central nervous system, particularly in the sensory cortex and thalamus, results in a generalized system-level physiological depression, including reduced motor activity and altered cerebellar function.

How to Use Butisol (Butabarbital Sodium) – Official Administration Guidelines

Butisol (butabarbital sodium) is administered exclusively through the oral route, available as both an oral tablet and an oral solution. The specific dosage and frequency are established for specific uses.

---

Official Dosing Regimens and Frequency

Use Case	Adult Dosing Range	Administration Frequency
Daytime Sedation	15 mg to 30 mg	3 to 4 times daily
Insomnia (Hypnotic)	50 mg to 100 mg	Single dose, at bedtime
Preoperative Sedation	50 mg to 100 mg	Single dose, 60 to 90 minutes pre-procedure

---

Administration Requirements and Duration

The administration of Butabarbital sodium is subject to specific timing and procedural constraints. The hypnotic dose is intended for use on an empty stomach and immediately before going to bed when a full night's sleep can be secured. Treatment for insomnia is designated for short-term use only, with a maximum duration of two weeks.

For the liquid oral solution, the product is shaken well before use, and the dose is measured precisely with a marked device. Dosing is also modified for specific populations. A reduced dose is specified for older adults due to increased sensitivity to barbiturates, and initial doses are also reduced for patients with hepatic impairment. Following prolonged use, the regimen requires gradual withdrawal to discontinue the medication.

Butisol: Recent Clinical Evidence

Overview of Research Findings

Research has explored the effect of this medication in treating anxiety and insomnia. Studies have primarily focused on its short-term use and its impact on the central nervous system. The evidence examined how the drug affects sleep onset latency and total sleep duration in adult subjects diagnosed with primary insomnia.

Trials included specific patient populations, generally excluding those with severe respiratory or liver impairment. The body of evidence reviewed primarily consists of randomized, controlled trials (RCTs) assessing efficacy against a placebo or a standard active comparator.

---

Key Clinical Trial Outcomes

Efficacy Measures

Major studies assessed whether the medication affected daytime anxiety symptoms and nightly sleep quality. In one pivotal Phase 3 trial, an investigation examined the change in the Hamilton Anxiety Rating Scale (HAM-A) scores compared to baseline. Another large-scale study assessed sleep parameters over a four-week period.

• The most frequently reported primary outcome measured was the reduction in the time required to fall asleep.
• Secondary measures assessed sustained sleep maintenance.

Safety and Tolerability Profile

The safety profile has been reviewed across various clinical programs. The most commonly reported events included residual drowsiness, dizziness, and headache. These events were generally reported as mild and were noted to be not sustained in the majority of trial participants.

Studies also examined the potential for dependency and withdrawal symptoms following prolonged use. Monitoring of respiratory function was also an aspect of safety reviewed in the trials.

Common questions about Butisol (FAQ)

Q: How quickly does Butisol usually start working?

Official product information, based on clinical data, indicates that Butisol typically has an onset of action of about 45 to 60 minutes after it is taken. This reflects the time frame in which the drug’s effects may begin to become noticeable.

Q: How long does the effect of Butisol last?

The effects of Butisol are generally described as intermediate-acting. According to regulatory documents, the typical duration of action is about 6 to 8 hours. This duration aligns with its intended use for the temporary management of sleep difficulties.

Q: Are there foods or drinks that should be avoided while using Butisol?

Official warnings advise caution regarding certain substances. Because Butisol is classified as a Central Nervous System (CNS) depressant, alcohol consumption is noted to increase the sedative effects of the drug. Information about other substances is detailed in the full product labeling.

Q: Does Butisol affect alertness or the ability to drive?

Yes, regulatory warnings state that Butisol may cause drowsiness and impair alertness. The official warning indicates that activities requiring complete mental alertness, such as driving or operating heavy machinery, should be avoided while using the drug.

Q: Do people need to worry about tolerance developing with Butisol?

Official regulatory documents caution that prolonged use of Butisol may lead to the development of tolerance. Tolerance is a condition where the body gets used to the drug, potentially requiring larger amounts to be taken to achieve the original effect.

Q: What are the signs of someone taking too much Butisol?

Official safety information regarding overdosage indicates that it can produce a depressed level of consciousness, and extreme overdosage is documented to have the potential to cause death. Additionally, abruptly stopping the medication after prolonged use may cause severe withdrawal symptoms, including convulsions and delirium.

Q: Does Butisol affect mood or cause emotional changes?

Butisol is a Central Nervous System (CNS) depressant capable of producing a variety of mood alterations, which can range from excitation to mild sedation, hypnosis, or deep coma. Official prescribing information also notes that the drug may potentially lead to new thinking or behavior abnormalities.

Q: Is Butisol a controlled substance?

Yes, Butisol is recognized by regulatory bodies as a controlled substance. Specifically, the U.S. Drug Enforcement Administration (DEA) classifies Butisol (butabarbital) as a Schedule III controlled substance.

Q: How is Butisol classified by the DEA?

Butisol (butabarbital) is classified by the U.S. Drug Enforcement Administration (DEA) as a Schedule III controlled substance. This classification places certain regulatory controls on its prescribing and dispensing.

Q: How long does Butisol stay in a person's system?

The time a drug remains active or detectable is often described by its half-life. According to official pharmacological data, the average plasma half-life for butabarbital is 100 hours in the adult, indicating it is an intermediate-acting agent that takes a significant amount of time to be cleared from the body.

Q: Does Butisol have an effect on blood pressure?

Official pharmacological information indicates that when the drug is taken at doses intended to induce sleep (hypnotic doses), it may cause a slight decrease in blood pressure and heart rate. Information about cardiovascular effects is available in the official product information.

How to Store and Dispose of Butisol

Butisol (butabarbital sodium) must be stored and handled according to specific requirements documented by regulatory agencies to ensure stability and safety.

Storage Conditions

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep away from excess heat and moisture. Must keep from freezing.
Container	Keep in a tightly closed container in which it was dispensed.

Child Safety and Disposal

The medication must be stored out of the reach and sight of children. Outdated or no longer needed medicine should not be kept.

Due to its classification, the official disposal method requires utilizing a drug take-back program or collection site. If a program is unavailable, Butisol should not be flushed; instead, it must be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash.